SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-026597
Filing Date
2024-03-27
Accepted
2024-03-27 16:07:37
Documents
15
Period of Report
2024-03-26
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0202742-8k_inmune.htm   iXBRL 8-K 23368
2 PRESS RELEASE DATED MARCH 26, 2024 ea020274201ex99-1_inmune.htm EX-99.1 13811
3 GRAPHIC ex99-1_001.jpg GRAPHIC 1829
  Complete submission text file 0001213900-24-026597.txt   218306

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE inmb-20240326.xsd EX-101.SCH 3018
5 XBRL LABEL FILE inmb-20240326_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE inmb-20240326_pre.xml EX-101.PRE 22361
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0202742-8k_inmune_htm.xml XML 3721
Mailing Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432
Business Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432 8589643720
Inmune Bio, Inc. (Filer) CIK: 0001711754 (see all company filings)

IRS No.: 475205835 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38793 | Film No.: 24790641
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)